Observational studyBreast cancer research and treatment2013
Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer.
Observational study in Breast cancer research and treatment, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.Internal and emergency medicine · 2016Pooled it
- A Real-World Evaluation of Racial Disparities in the Receipt of Cancer Treatments and Anthracycline-Based Chemotherapies in Early-Stage Breast Cancer Patients.Journal of racial and ethnic health disparities · 2026Article
- Racial and ethnic disparities in neoadjuvant chemotherapy patterns and outcomes in early-stage HER2-positive breast cancer.NPJ breast cancer · 2025Article
- Non-believer to Believer: A Podcast Conversation on the Journey from Skeptic to Proponent of Oncology Real-World Evidence.Oncology and therapy · 2025Article
- Real-world treatment patterns among patients diagnosed with hormone receptor-positive metastatic breast cancer in the USA.British journal of clinical pharmacology · 2025Observational
- Article
- Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer.Cardio-oncology (London, England) · 2024Article
- Exploring the complexity and spectrum of racial/ethnic disparities in colon cancer management.International journal for equity in health · 2023Article
- Lifestyle factors in Black female breast cancer survivors-Descriptive results from an online pilot study.Frontiers in public health · 2023Article
- Article
- Inequity in Cardio-Oncology: Identifying Disparities in Cardiotoxicity and Links to Cardiac and Cancer Outcomes.Journal of the American Heart Association · 2021Review
- Racial disparities in survival outcomes among breast cancer patients by molecular subtypes.Breast cancer research and treatment · 2021Article
- Untreated head and neck cancer: Natural history and associated factors.Head & neck · 2021Article
- The Impact of Primary Tumor Surgery on Survival in HER2 Positive Stage IV Breast Cancer Patients in the Current Era of Targeted Therapy.Annals of surgical oncology · 2020Article
- Using Phosphatidylinositol Phosphorylation as Markers for Hyperglycemic Related Breast Cancer.International journal of molecular sciences · 2020Article
- Article
- Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets.BMC medical genomics · 2019Article
- Literature review of data-based models for identification of factors associated with racial disparities in breast cancer mortality.Health systems (Basingstoke, England) · 2019Review
- Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.Cancer · 2018Article
- Racial disparity in breast cancer: can it be mattered for prognosis and therapy.Journal of cell communication and signaling · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data characterizing demographics, treatment patterns, and clinical outcomes in black patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) are limited. registHER is a large, observational cohort study of patients (n = 1,001) with HER2-positive MBC diagnosed ≤6 months of enrollment and followed until death, disenrollment, or June 2009 (median follow-up of 27 months). Demographics, treatment patterns, and clinical outcomes were described for black (n = 126) and white patients (n = 793). Progression-free survival (PFS) following first-line therapy and overall survival (OS) were examined. Multivariate analyses adjusted for baseline and treatment factors. Black patients were more likely than white patients to be obese (body mass index ≥30), to have diabetes, and to have a history of cardiovascular disease; they were also less likely to have estrogen receptor or progesterone receptor positive disease. In patients treated with trastuzumab, the incidence of cardiac safety events (grade ≥3) was higher in black patients (10.9 %) than in white patients (7.9 %). Unadjusted median OS and PFS (months) were significantly lower in black patients than in white patients (OS: black: 27.1, 95 % confidence interval [CI] 21.3-32.1; white: 37.3, 95 % CI 34.6-41.1; PFS: black: 7.0, 95 % CI 5.7-8.2; white: 10.2, 95 % CI 9.3-11.2). The adjusted OS hazard ratio (HR) for black patients compared with white patients was 1.29 (95 % CI 1.00-1.65); adjusted PFS HR was 1.29 (95 % CI 1.05-1.59). This real-world evaluation of a large cohort of patients with HER2-positive MBC shows poorer prognostic factors and independently worse clinical outcomes in black versus white patients. Further research is needed to identify potential biologic differences that could have predictive impact for black patients or that could explain these differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.